長春高新(000661.SZ):金賽藥業擬分三個階段以增資形式取得椿安生物51%股權
格隆匯3月16日丨長春高新(000661.SZ)公佈,公司子公司長春金賽藥業有限責任公司(“金賽藥業”)擬與上海椿安生物醫藥科技有限公司(“椿安生物”)就收購股權事項共同簽署《上海椿安生物醫藥科技有限公司增資擴股協議》。金賽藥業以其自有資金擬分三個階段以增資擴股形式合計收購椿安生物51%股權。
此次是第一階段,即按照椿安生物當前估值,收購椿安生物30%股權,該階段投資總額預計10285.7148萬元人民幣。
此次投資後可以充分利用椿安生物現有分子耦聯技術平台,開發符合公司戰略的新產品,同時有利於拓寬公司業務結構,使公司快速進入老年骨關節疾病和皮膚科領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.